top of page

Adjunctive Effects of Psilocybin and Buprenorphine

About the study

NCT Trial Number

NCT04161066

The drug being studied

Psilocybin

noun_Drug_2240951.png
noun_Institution_118530.png

Sponsored by

University of Wisconsin, Madison
Heffter Research Institute

noun_date_3237048.png

Trial Start Date

Aug-20

noun_capsule_138144.png

About the participants

Age seeking

21 Years to 65 Years

gender

All

noun_Mental Health_2683241.png

Primary condition of volunteers accepted

Opioid Use Disorder

noun_square_138133.png

Accepts healthy volunteers?

No

This study will determine the safety of psilocybin to treat patients with opioid use disorder who are currently taking buprenorphine/naloxone.

Eyes Graffiti

Locations

United States, Wisconsin

University of Wisconsin
Madison, Wisconsin, United States, 53705

Contact: Bri Deyo, MPH
608-225-0718
protea.research@mailplus.wisc.edu

​

​

​

​

Get in contact

Find a study site convenient for you below, then email yourself the contact details and next steps

bottom of page